02:41 , Mar 15, 2019 |  BC Innovations  |  Product Development

Fresh AIMMs for elite responders

AIMM Therapeutics B.V.’s elite responder platform has identified mAbs that distinguish tumor and healthy cells based on protein modifications. The company is one of a handful of players mining the immune systems of cancer patients...
23:56 , Feb 25, 2019 |  BC Extra  |  Company News

Management tracks: Viriom, Matinas, Atreca

Viriom Inc. (San Diego, Calif.) hired Iain Dukes as CEO, a new position at the antiviral company. He is a venture partner at OrbiMed Advisors and serves as chairman of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) as...
23:48 , Sep 14, 2018 |  BioCentury  |  Finance

Solidifying Atreca’s repertoire

Atreca Inc. parlayed preclinical proof-of-concept data from its antibody platform into a $125 million series C round, which will enable the cancer immunotherapy company to bring its two lead programs into the clinic. An undisclosed,...
19:16 , Sep 14, 2018 |  BC Week In Review  |  Financial News

Atreca’s $125M round paves way for first immunotherapy into clinic

Atreca Inc. (Redwood City, Calif.) raised $125 million in a series C round led by an undisclosed U.S.-based healthcare fund, clearing the way for the company to move its first cancer immunotherapy into the clinic....
04:01 , Sep 12, 2018 |  BC Extra  |  Financial News

Atreca’s $125M round paves way for first immunotherapy into clinic

Atreca Inc. (Redwood City, Calif.) raised $125 million in a series C round led by an undisclosed U.S.-based healthcare fund, clearing the way for the company to move its first cancer immunotherapy into the clinic....
16:29 , Aug 18, 2017 |  BC Week In Review  |  Financial News

Atreca raises $35M in series B

On Aug. 17, cancer immunotherapy company Atreca Inc. (Redwood City, Calif.) raised $35 million in a series B round co-led by new investor Wellington Management and an undisclosed U.S. healthcare fund, which is an existing...
19:03 , Aug 17, 2017 |  BC Extra  |  Financial News

Atreca raises $35M in series B

Cancer immunotherapy company Atreca Inc. (Redwood City, Calif.) raised $35 million in a series B round co-led by new investor Wellington Management and an undisclosed U.S. healthcare fund, which is an existing investor. New investor...
20:33 , Jun 2, 2017 |  BC Week In Review  |  Company News

Atreca, Dana-Farber to study mechanisms of cancer immunotherapy

Atreca Inc. (Redwood City, Calif.) and Dana-Farber Cancer Institute (Boston, Mass.) partnered to study active immune response in cancer patients who respond to immunotherapy. The partners will use Atreca’s Immune Repertoire Capture technology to study...
22:41 , Jan 19, 2017 |  BC Innovations  |  Finance

IMI branches out

The Innovative Medicines Initiative (IMI) is broadening its base in its latest call for proposals by bringing in funding partners from the non-profit sector. The new partners will add to the portfolio of projects backed...
07:00 , Aug 8, 2016 |  BioCentury  |  Emerging Company Profile

Interrogating immunity

OncoResponse Inc. is repurposing Theraclone Sciences Inc .'s I-STAR discovery platform to identify antibodies produced by exceptional responders to cancer immunotherapy. By tapping patients' natural immune responses, OncoResponse hopes to find novel immune targets and...